Skip to main content
. 2019 Apr 26;39(4):BSR20182293. doi: 10.1042/BSR20182293

Figure 8. Akt and MEK/ERK1/2 execute parallel signaling pathways that increase fibronectin expression.

Figure 8

(A) MCs were pretreated with MK-2206, a specific Akt kinase inhibitor, prior to PTHrP (1–34) incubation for 1 h. ERK1/2 phosphorylation was detected by western blot (*P<0.05 vs control, n=4). (B) MCs were pretreated with U0126, a specific MEK inhibitor, prior to PTHrP (1–34) treatment for 1 h. Akt phosphorylation at S473 was assessed by western blot (*P<0.05 vs control, n=3). (C) Diabetic SD rats were untreated or treated with PTHrP (1–34) by s.c. injection at 40, 80, or 160 μg/kg body weight for 3 months. The phosphorylation level of ERK1/2 in renal cortex was detected by western blot (*P<0.05 vs control, #P<0.05 vs STZ group, n=8). (D) MCs were pretreated with specific MEK inhibitor, PD98059 or U0126, followed by PTHrP (1–34) incubation for 24 h. The protein level of fibronectin was assessed by western blot, with β-actin used as loading control (*P<0.05 vs control, n=4).